All In Biotech

Drug Trial Radar · NCT01074697

Efficacy of Two Antiemetic Regimens in Patients Receiving Radiotherapy and Concomitant Weekly Cisplatin

A Multinational, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Tolerability of Palonosetron and Dexamethasone Plus Fosaprepitant or Placebo in Patients Receiving Radiotherapy and Weekly Cisplatin.

Last checked: Nov 19, 2026Latest source record: Apr 24, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 246 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

246

Actual

Start

Apr 2010

Primary completion

Apr 2015

Study completion Apr 2015

Sponsor

Lead sponsor
Odense University HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Helsinn Healthcare SA
First posted
Feb 24, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Supportive care
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

GAND-emesis is a multinational, randomized, double-blind, placebo-controlled, parallel-group study to investigate the efficacy and tolerability of a neurokinin1 receptor antagonist (fosaprepitant dimeglumine) in combination with an antiemetic (anti-nausea-and-vomiting) control regimen (palonosetron and dexamethasone) in patients with a gynaecological cancer diagnosis, who are scheduled to receive radiotherapy and weekly chemotherapy. The study aims at investigating if a three-drug antiemetic regimen is superior to a two-drug regimen (standard treatment) in preventing nausea and vomiting in patients receiving radiotherapy and weekly chemotherapy. A pilot study demonstrated that approximately 50% of patients will experience nausea and vomiting when offered a two-drug antiemetic regimen, and it is expected that addition of a third drug (a neurokinin1 receptor antagonist) can increase the proportion of patients with no vomiting in the course of combined chemo-radiotherapy.

Conditions

  • Nausea
  • Vomiting
  • Genital Neoplasms, Female

Interventions

  • Fosaprepitant dimeglumineDrug

    Addition of fosaprepitant dimeglumine 150 mg IV single dose weekly (before chemotherapy) to dexamethasone and palonosetron.

  • PlaceboDrug

    Saline water

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To compare fosaprepitant dimeglumine, palonosetron, and dexamethasone with palonosetron, dexamethasone, and placebo with respect to efficacy; the proportion of subjects with no vomiting during five weeks of radiotherapy and concomitant weekly cisplatin.Time frame: 35 days

Locations

8 sites in 4 countries. Site status is shown where the registry gives one.

  • RAH Cancer Centre, Royal Adelaide Hospital

    Adelaide SA, Australia

  • Department of Oncology

    Aarhus, Denmark

  • Rigshospitalet, Finsen Centret

    Copenhagen, Denmark

  • Herlev Hospital

    Herlev, Denmark

  • Department of Oncology, Odense University Hospital

    Odense, Denmark

  • Vivantes Klinikum Neukolln

    Berlin, Germany

  • Universitatsklinikum Schleswig Holstein

    Kiel, Germany

  • The Norwegian Radium Hospital

    Oslo, Norway

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.